XOMA (NASDAQ:XOMA) Cut to Sell at StockNews.com

StockNews.com cut shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a research report sent to investors on Wednesday.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $123.00 target price on shares of XOMA in a report on Tuesday.

XOMA Price Performance

XOMA opened at $25.18 on Wednesday. XOMA has a 1 year low of $18.57 and a 1 year high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company has a market capitalization of $296.70 million, a price-to-earnings ratio of -7.24 and a beta of 0.92. The firm’s fifty day moving average price is $29.11 and its two-hundred day moving average price is $27.92.

Insider Activity at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the sale, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in XOMA. Bank of New York Mellon Corp grew its position in shares of XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Rhumbline Advisers boosted its stake in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,334 shares during the period. Ellsworth Advisors LLC purchased a new position in XOMA during the third quarter worth about $516,000. BNP Paribas Financial Markets increased its stake in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.